The Desensitization Therapy With GB-0998 for Anti-donor Antibody-positive Recipients.
Status:
Completed
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
It is intended to examine the safety and efficacy of desensitization therapy by GB-0998
(intravenous immunoglobulin) for the anti-donor antibody positive recipient in need of
pre-transplant desensitization. Patients with positive FCXM-T after performing twice double
filtration plasmapheresis (DFPP) therapy will receive GB-0998 1g/kg/day for four days.